What are the indications and recommended dosing of ursodeoxycholic acid (ursodiol) for primary biliary cholangitis and cholesterol gallstone dissolution in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ursodeoxycholic Acid (Ursodiol): Indications and Dosing

Primary Biliary Cholangitis (PBC)

Ursodeoxycholic acid at 13-15 mg/kg/day is the first-line treatment for all patients with PBC and should be initiated immediately upon diagnosis. 1, 2

Dosing for PBC

  • Standard dose: 13-15 mg/kg/day divided into 2-3 doses 1
  • This dosing improves liver biochemistry, delays histological progression, and reduces the likelihood of liver transplantation or death, particularly in patients with moderate to severe disease 1
  • Do not exceed 15 mg/kg/day - higher doses provide no additional benefit and increasing beyond this threshold is not indicated even for persistent alkaline phosphatase elevation 2
  • Continue UDCA even if alkaline phosphatase remains elevated, as it still provides sustained survival benefits 2

Key Clinical Points for PBC

  • UDCA works through multiple mechanisms: protecting cholangiocytes from toxic bile acids, stimulating hepatobiliary secretion, and inhibiting apoptosis 1
  • Biochemical response should be assessed at 1 year, with near-normalization of alkaline phosphatase as the target 3
  • Approximately two-thirds of patients respond adequately to UDCA 3
  • Critical pitfall: Many patients in the UK are underdosed; over one-third of partial responders become full responders when UDCA is increased to the recommended 13-15 mg/kg/day 3
  • UDCA is safe during pregnancy and breastfeeding and should be continued 4

Primary Sclerosing Cholangitis (PSC)

UDCA is NOT recommended for routine treatment of newly diagnosed PSC. 5, 6

Evidence Against Use in PSC

  • Multiple trials show UDCA improves liver biochemistry but does not improve clinical outcomes (death, transplantation, or disease progression) 5, 6
  • High-dose UDCA (28-30 mg/kg/day) is harmful - a multicenter trial was terminated early due to increased rates of death, liver transplantation, and variceal development in the UDCA group 6, 1, 6
  • Low to moderate doses (10-23 mg/kg/day) show no survival benefit 5, 1, 6

Exception

  • In PSC with autoimmune hepatitis overlap syndrome, corticosteroids and immunosuppressants are recommended, not UDCA 5

Cholesterol Gallstone Dissolution

For radiolucent cholesterol gallstones: 8-10 mg/kg/day divided into 2-3 doses. 7

Dosing and Monitoring for Gallstones

  • FDA-approved dose: 8-10 mg/kg/day 7
  • Ultrasound monitoring at 6-month intervals during the first year 7
  • Complete dissolution expected in approximately 30% of unselected patients with uncalcified stones <20 mm treated for up to 2 years 7
  • Best candidates: Floating stones (high cholesterol content), stones ≤5 mm diameter (81% dissolution rate), stones <20 mm 7
  • Poor candidates: Calcified stones, stones >20 mm, non-visualizing gallbladder on treatment 7

Treatment Duration and Outcomes

  • If partial dissolution is not seen by 12 months, likelihood of success is greatly reduced 7
  • Continue therapy after apparent dissolution and confirm on repeat ultrasound within 1-3 months 7
  • Stone recurrence occurs in 30-50% of patients within 2-5 years after complete dissolution 7

Alternative Dosing Strategy

  • Bedtime administration at 8.4 mg/kg/day may be more effective than divided mealtime dosing, reducing the cholesterol saturation index more efficiently 8

Gallstone Prevention During Rapid Weight Loss

For obese patients undergoing rapid weight loss: 600 mg/day (300 mg twice daily). 7

This prophylactic dose is specifically for patients with BMI ≥38 undergoing very low-calorie diets 7.

Safety Profile

  • Excellent tolerability with minimal adverse effects 1, 2
  • Dose-dependent diarrhea is the primary side effect 9
  • No significant hepatotoxicity or increase in lithocholic acid-related liver injury 1, 7
  • Safe during pregnancy and lactation 4, 9
  • Does not improve pruritus or fatigue in PBC 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.